Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FWUWK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $98,899
Award facts
- Contract value 100% obligated
- $98,898.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $98,898.60 to DMS Pharmaceutical Group Inc. on September 10, 2025, for the supply of ENTYVIO 300 mg vials. This delivery order, which falls under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999 and valid through November 2026, represents a continuation of the company's role as a critical pharmaceutical supplier to the federal government. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete directly based on its capabilities as a woman-owned small business pharmaceutical wholesaler. Performance is scheduled for completion by October 1, 2025, with delivery to Park Ridge, Illinois.
DMS Pharmaceutical Group Inc., headquartered in Park Ridge, Illinois, is a woman-owned small business registered in SAM.gov since 2001 that specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare facilities. Under the broader SPE2DB program umbrella, the company maintains a robust portfolio of pharmaceutical product deliveries to the DLA, supplying specialized medications ranging from oncology treatments to vaccines and injectable therapeutics. This delivery order for ENTYVIO, a gastrointestinal biologic medication, continues DMS Pharmaceutical Group's established position as a key distributor supporting Department of Defense healthcare operations nationwide.
Quick answers
Who was awarded contract SPE2DB25FWUWK?
SPE2DB25FWUWK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 10, 2025.
How much is contract SPE2DB25FWUWK worth?
The government has obligated $98,899 on SPE2DB25FWUWK.
Is contract SPE2DB25FWUWK an order under another contract?
Yes. SPE2DB25FWUWK is a delivery order under SPE2DB25D9312, an indefinite delivery contract.
Was contract SPE2DB25FWUWK competed?
The extent of competition for SPE2DB25FWUWK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award